SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET.

Recent Highlights:

Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 million
Announced strategic sale of SomaLogic to Illumina for up to $425 million in total cash consideration plus future royalties, expected to close in the first half of 2026
$240 million in cash & cash equivalents as of June 30, 2025; At least $550 million in cash & cash equivalents expected at close of transaction with Illumina to fuel inorganic growth strategy
Targeting adjusted EBITDA break-even in 2026

"The second quarter was a clear demonstration of our strategy in action. Our team delivered another solid quarter of performance, even as U.S. Academic spend remained under pressure, while taking meaningful steps to transform the business," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "The announced sale of SomaLogic to Illumina marks a pivotal milestone in that evolution – unlocking up to $425 million in total cash consideration with additional upside levers and further validating the power of our model."

Egholm continued, "With at least $550 million in cash & cash equivalents expected at close and a simplified operating infrastructure, we are driving toward our profitability target in 2026. The combination of a strong balance sheet and a lean operating model positions us to continue playing offense — strategically deploying capital into high-quality, underappreciated assets – to drive scale, reignite growth and create long-term value for our shareholders."

Financial Results Table: Continuing Operations

	Three Months Ended June 30,						Six Months Ended June 30,
*(Unaudited, in millions, except percentages)*	2025			2024			2025			2024
Revenue	$	21.8		$	22.5		$	42.0		$	44.1
Gross margin		48.8	%		46.1	%		51.6	%		48.5	%
Non-GAAP gross margin		54.1	%		48.6	%		55.6	%		54.1	%
Operating expenses	$	36.3		$	40.6		$	74.3		$	96.1
Non-GAAP operating expenses	$	27.9		$	28.3		$	53.5		$	58.2
Operating loss	$	(25.7	)	$	(30.3	)	$	(52.7	)	$	(74.7	)
Net loss from continuing operations	$	(17.7	)	$	(25.4	)	$	(41.0	)	$	(41.8	)
Adjusted EBITDA	$	(16.1	)	$	(17.4	)	$	(30.2	)	$	(34.3	)
Cash, cash equivalents, restricted cash, and short-term investments	$	239.7		$	397.2		$	239.7		$	397.2

Second Quarter 2025 Financial Results: Continuing Operations

Following the announced sale of SomaLogic in June 2025, all financial results in this section reflect continuing operations only.

Revenue was $21.8 million in the second quarter of 2025, down 3% year-over-year, and $42 million for the first half of 2025, down 5% year-over-year:
- Consumables revenue was $10.5 million in the second quarter of 2025, up 18% year-over-year, and $18.6 million for the first half of 2025, down 3% year-over-year. Consumables revenue in the quarter increased across imaging, flow and microfluidics product lines.
- Instruments revenue was $5.2 million in the second quarter of 2025, down 26% year-over-year, and $11.9 million for the first half of 2025, down 1% year-over-year. Instrument revenue in the quarter was impacted by capital constrained end-markets globally.
- Services revenue, which is predominantly Field Services, was $6.1 million in the second quarter of 2025, down 8% year-over-year, and $11.5 million for the first half of 2025, down 11% year-over-year. Field Services revenue decreased due to fewer active service contracts and lower on-demand revenue driven by improved instrument quality and uptime.

Gross margins in the second quarter of 2025 were approximately 48.8%, versus 46.1% in the second quarter of 2024; and non-GAAP gross margins in the second quarter of 2025 were approximately 54.1%, versus 48.6% in the second quarter of 2024. Gross margins in the first half of the year were 51.6% in 2025 and 48.5% in 2024; and non-GAAP gross margins were approximately 55.6% in the first half of 2025 and 54.1% for the same period in 2024. Gross margins and non-GAAP gross margins were driven by product mix and incremental improvements from Standard BioTools Business System (SBS).
Operating expenses in the second quarter of 2025 were $36.3 million, a decrease of $4.3 million, or down 11%, compared to the second quarter of 2024; and non-GAAP operating expenses, which exclude transaction costs, stock-based compensation, and restructuring charges, were $27.9 million in the second quarter of 2025, a decrease of $0.4 million, or down 1%, compared to the second quarter of 2024. For the first half of 2025, operating expenses decreased by $21.8 million, or 23%, compared to the first half of 2024, to $74.3 million, while non-GAAP operating expenses decreased by $4.7 million, or 8%, compared to the same period in 2024, to $53.5 million. The decrease in operating expenses is a result of the realization of merger cost synergies and continued productivity gains from SBS.
Net loss for the second quarter of 2025 was $17.7 million, compared to a net loss of $25.4 million in the second quarter of 2024, representing a decrease of $7.7 million or 31%, while adjusted EBITDA for the second quarter of 2025 was a loss of $16.1 million, versus an adjusted EBITDA loss of $17.4 million in the second quarter of 2024, an improvement of $1.2 million, or 7%. Net loss for the first half improved by $0.8 million at $41.0 million while adjusted EBITDA increased by $4.1 million, or 12%, compared to the first half of 2024, to a loss of $30.2 million.

Full Year 2025 Revenue Outlook

For fiscal year 2025, the Company expects combined revenue in the range of $165 million to $175 million. Revenue from continuing operations is expected in the range of $78 million to $83 million.

This combined outlook continues to assume a high single-digit millions decline in our Americas academic revenue due to anticipated NIH funding pressures, with a more pronounced impact on our continuing operations. It also assumes no expected effect from U.S. export controls and limited impact from tariffs.

Conference Call Information

Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. In connection with the pending sale of SomaLogic and operational focus, the Company is temporarily pausing earnings conference calls until further notice.

All financial results and related disclosures are available in this press release and will be available in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Use of Non-GAAP Financial Information

Standard BioTools has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis. The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company's core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company's core operating results. Management uses non-GAAP measures to compare the Company's performance relative to forecasts and strategic plans and to benchmark the Company's performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company's operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance, including with respect to future revenue and expected cash at the closing of the transaction with Illumina; operational and strategic plans; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits and synergies of prior and potential future acquisitions, including the potential for such transactions to drive long-term profitable growth. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the anticipated benefits and synergies of announced divestures and prior and potential future acquisitions and the integration of any such businesses, including the potential for such transactions to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from such transactions; possible integration, restructuring and transition-related disruption resulting from such transactions, including through the loss of customers, suppliers, and employees and adverse impacts on the Company's development activities and results of operation; the timing of the closing of the transaction with Illumina and the operating expenses over the intervening period; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company's plans, or both; risks that the Company's expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company's business or external market conditions; anticipated NIH funding pressures; the expected effect from U.S. export controls and the expected impact from tariffs; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company's products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company's research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the "Risk Factors" section of the Company's annual report on Form 10-K filed with the SEC on March 11, 2025, the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the SEC, and in the Company's other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.

About Standard BioTools Inc.

Standard BioTools Inc. (NASDAQ:LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.

Patent and License Information: standardbio.com/legal/notices.

Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2025 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Investor Contact:

ir@standardbio.com


STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Continuing Operations (In thousands, except per share amounts) (Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Revenue:
Product revenue	$	15,673		$	15,894		$	30,454		$	31,208
Services and other revenue		6,089			6,598			11,530			12,937
Total revenue		21,762			22,492			41,984			44,145
Cost of revenue:
Cost of product revenue		7,608			7,771			14,039			15,617
Cost of services and other revenue		3,526			4,347			6,268			7,129
Total cost of revenue		11,134			12,118			20,307			22,746
Gross profit		10,628			10,374			21,677			21,399
Operating expenses:
Research and development		6,222			7,244			11,662			14,852
Selling, general and administrative		28,105			24,860			57,929			51,274
Restructuring and related charges		1,727			5,749			3,279			10,033
Transaction and integration expenses		271			2,782			1,474			19,945
Total operating expenses		36,325			40,635			74,344			96,104
Loss from continuing operations		(25,697	)		(30,261	)		(52,667	)		(74,705	)
Bargain purchase gain		—			—			—			25,213
Interest income		2,461			5,302			5,377			11,509
Interest expense		(9	)		(858	)		(11	)		(1,891	)
Other income (expense), net		4,963			412			5,530			(1,822	)
Loss from continuing operations before income taxes		(18,282	)		(25,405	)		(41,771	)		(41,696	)
Income tax benefit (expense)		609			(39	)		728			(152	)
Net loss from continuing operations		(17,673	)		(25,444	)		(41,043	)		(41,848	)
Discontinued operations:
Loss from discontinued operations, net of tax		(15,786	)		(20,274	)		(18,449	)		(36,027	)
Net loss		(33,459	)		(45,718	)		(59,492	)		(77,875	)
Induced conversion of redeemable preferred stock		—			—			—			(46,014	)
Net loss attributable to common stockholders	$	(33,459	)	$	(45,718	)	$	(59,492	)	$	(123,889	)
Net loss per share from continuing operations, basic and diluted	$	(0.05	)	$	(0.07	)	$	(0.11	)	$	(0.26	)
Net loss per share from discontinued operations, basic and diluted	$	(0.04	)	$	(0.05	)	$	(0.05	)	$	(0.11	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.09	)	$	(0.12	)	$	(0.16	)	$	(0.37	)
Shares used in computing net loss per share attributable to common stockholders, basic and diluted		380,498			372,331			379,369			333,228

STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED BALANCE SHEETS Continuing Operations (In thousands) (Unaudited)

	June 30,		December 31,
	2025		2024
ASSETS
Current assets:
Cash and cash equivalents	$	158,617	$	166,728
Short-term investments		78,468		126,146
Accounts receivable, net		14,612		14,741
Inventory		24,170		20,744
Prepaid expenses and other current assets		7,081		4,561
Current assets held for sale		223,089		42,963
Total current assets		506,037		375,883
Property and equipment, net		22,678		22,775
Operating lease right-of-use asset, net		24,568		26,567
Other non-current assets		3,682		3,688
Non-current assets held for sale		—		183,432
Total assets	$	556,965	$	612,345

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	7,329	$	5,049
Accrued liabilities		24,207		21,435
Operating lease liabilities, current		5,094		4,806
Deferred revenue, current		40,167		10,274
Deferred grant income, current		3,243		3,527
Current liabilities held for sale		17,984		20,804
Total current liabilities		98,024		65,895
Convertible notes, non-current		299		299
Deferred tax liability		1,081		1,081
Operating lease liabilities, non-current		23,223		25,590
Deferred revenue, non-current		2,786		32,674
Deferred grant income, non-current		5,767		7,243
Other non-current liabilities		1,250		1,062
Non-current liabilities held for sale		—		6,779
Total liabilities		132,430		140,623
Total stockholders' equity		424,535		471,722
Total liabilities and stockholders' equity	$	556,965	$	612,345

STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)

	Six Months Ended June 30,
	2025			2024
Operating activities
Net loss	$	(59,492	)	$	(77,875	)
Bargain purchase gain		—			(25,213	)
Stock-based compensation expense		15,396			18,341
Amortization of acquired intangible assets		1,715			2,822
Depreciation and amortization		6,450			6,228
Accretion of discount on short-term investments, net		(1,571	)		(4,544	)
Non-cash lease expense		2,865			2,949
Provision for excess and obsolete inventory		1,360			1,874
Change in fair value of warrants		(232	)		(453	)
Change in fair value of contingent consideration		(3,400	)		—
Other non-cash items		477			868
Changes in assets and liabilities, net		(14,519	)		(26,523	)
Net cash used in operating activities		(50,951	)		(101,526	)

Investing activities
Cash and restricted cash acquired in merger		—			280,033
Purchases of short-term investments		(50,929	)		(147,984	)
Proceeds from sales and maturities of investments		100,000			239,000
Purchases of property and equipment		(6,941	)		(2,718	)
Net cash provided by investing activities		42,130			368,331

Financing activities
Repayment of term loan and convertible notes		—			(8,192	)
Payment of term loan fee		—			(545	)
Repurchase of common stock		—			(40,490	)
Proceeds from ESPP stock issuance		308			425
Payments for taxes related to net share settlement of equity awards and other		(246	)		(344	)
Proceeds from exercise of stock options		—			1,052
Net cash provided by (used in) financing activities		62			(48,094	)
Effect of foreign exchange rate fluctuations on cash and cash equivalents		1,145			(110	)
Net (decrease) increase in cash, cash equivalents and restricted cash		(7,614	)		218,601
Cash, cash equivalents and restricted cash at beginning of period		168,818			52,499
Cash, cash equivalents and restricted cash at end of period	$	161,204		$	271,100

Cash, cash equivalents, and restricted cash consists of:
Cash and cash equivalents	$	158,617		$	269,811
Restricted cash		2,587			1,289
Total cash, cash equivalents and restricted cash	$	161,204		$	271,100

STANDARD BIOTOOLS INC. REVENUE Continuing Operations (In thousands) (Unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Product revenue:
Instruments	$	5,215	$	7,047	$	11,861	$	11,950
Consumables		10,458		8,847		18,593		19,258
Total product revenue		15,673		15,894		30,454		31,208
Services and other revenue		6,089		6,598		11,530		12,937
Total revenue	$	21,762	$	22,492	$	41,984	$	44,145

STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Continuing Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Gross profit	$	10,628		$	10,374		$	21,677		$	21,399
Amortization of acquired intangible assets		—			3			—			1,407
Depreciation and amortization		554			332			817			699
Stock-based compensation expense		402			221			644			383
Loss on disposal of property and equipment		187			—			187			—
Cost of sales adjustment		—			—			—			—
Non-GAAP gross profit	$	11,771		$	10,930		$	23,325		$	23,888

Gross margin percentage		48.8	%		46.1	%		51.6	%		48.5	%
Amortization of acquired intangible assets		—			—			—			3.1	%
Depreciation and amortization		2.6	%		1.5	%		2.0	%		1.6	%
Stock-based compensation expense		1.8	%		1.0	%		1.6	%		0.9	%
Loss on disposal of property and equipment		0.9	%		—			0.4	%		—
Cost of sales adjustment		—			—			—			—
Non-GAAP gross margin percentage		54.1	%		48.6	%		55.6	%		54.1	%

STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Continuing Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Operating expenses	$	36,325		$	40,635		$	74,344		$	96,104
Restructuring and related charges		(1,727	)		(5,749	)		(3,279	)		(10,033	)
Transaction and integration expenses		(271	)		(2,782	)		(1,474	)		(19,945	)
Stock-based compensation expense		(4,970	)		(3,189	)		(12,777	)		(6,595	)
Amortization of acquired intangible assets		—			77			—			—
Depreciation and amortization		(1,451	)		(674	)		(3,277	)		(1,295	)
Loss on disposal of property and equipment		—			(9	)		—			(23	)
Non-GAAP operating expenses	$	27,906		$	28,309		$	53,537		$	58,213

R&D operating expenses	$	6,222		$	7,244		$	11,662		$	14,852
Stock-based compensation expense		(481	)		(238	)		(820	)		(644	)
Depreciation and amortization		(630	)		(130	)		(769	)		(289	)
Gain on disposal of property and equipment		56			—			28			—
Non-GAAP R&D operating expenses	$	5,167		$	6,876		$	10,101		$	13,919

SG&A operating expenses	$	28,105		$	24,860		$	57,929		$	51,274
Stock-based compensation expense		(4,489	)		(2,951	)		(11,957	)		(5,951	)
Amortization of acquired intangible assets		—			77			—			—
Depreciation and amortization		(821	)		(544	)		(2,508	)		(1,006	)
Loss on disposal of property and equipment		(56	)		(9	)		(28	)		(23	)
Non-GAAP SG&A operating expenses	$	22,739		$	21,433		$	43,436		$	44,294

STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Continuing Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Net loss	$	(17,673	)	$	(25,444	)	$	(41,043	)	$	(41,848	)
Income tax (benefit) expense		(609	)		39			(728	)		152
Interest income		(2,461	)		(5,302	)		(5,377	)		(11,509	)
Interest expense		9			858			11			1,891
Amortization of acquired intangible assets		—			(74	)		—			1,407
Depreciation and amortization		2,005			1,006			4,094			1,994
Bargain purchase gain		—			—			—			(25,213	)
Restructuring and related charges		1,727			5,749			3,279			10,033
Transaction and integration expenses		271			2,782			1,474			19,945
Stock-based compensation expense		5,372			3,410			13,421			6,978
Cost of sales adjustment		—			—			—			—
Loss on disposal of property and equipment		187			9			187			23
Other non-operating (income) expense		(4,963	)		(412	)		(5,530	)		1,822
Adjusted EBITDA	$	(16,135	)	$	(17,379	)	$	(30,212	)	$	(34,325	)

STANDARD BIOTOOLS INC. Condensed Results of Operations Discontinued Operations (In thousands) (Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Revenue	$	20,200		$	14,713		$	40,773		$	38,600
Cost of revenue		11,552			10,176			23,432			20,904
Selling, general and administrative expenses		8,216			12,849			17,099			33,378
Research and development		5,850			11,977			11,738			20,350
Transaction and integration expenses		10,507			-			10,507			-
Other (income) expense, net		(139	)		(15	)		(3,554	)		(5	)
Total expenses	$	35,986		$	34,987		$	59,222		$	74,627
Loss from discontinued operations	$	(15,786	)	$	(20,274	)	$	(18,449	)	$	(36,027	)

STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Discontinued Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Gross profit	$	8,649		$	4,534		$	17,342		$	17,697
Amortization of acquired intangible assets		653			552			1,370			1,104
Depreciation and amortization		879			635			1,352			1,292
Stock-based compensation expense		161			73			414			150
Loss on disposal of property and equipment		26			—			58			—
Cost of sales adjustment		—			—			—			(1,812	)
Non-GAAP gross profit	$	10,368		$	5,794		$	20,536		$	18,431

Gross margin percentage		42.8	%		30.8	%		42.5	%		45.8	%
Amortization of acquired intangible assets		3.2	%		3.8	%		3.5	%		2.9	%
Depreciation and amortization		4.4	%		4.3	%		3.3	%		3.3	%
Stock-based compensation expense		0.8	%		0.5	%		1.0	%		0.4	%
Loss on disposal of property and equipment		0.1	%		—			0.1	%		—
Cost of sales adjustment		—			—			—			(4.7	)%
Non-GAAP gross margin percentage		51.3	%		39.4	%		50.4	%		47.7	%

STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Discontinued Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Operating expenses	$	24,756		$	24,792		$	39,448		$	53,693
Restructuring and related charges		(104	)		—			(104	)		—
Transaction and integration expenses		(10,507	)		—			(10,507	)		—
Stock-based compensation expense		(852	)		(3,247	)		(1,561	)		(11,213	)
Amortization of acquired intangible assets		(164	)		(238	)		(345	)		(311	)
Depreciation and amortization		(293	)		(1,498	)		(1,004	)		(2,942	)
Loss on disposal of property and equipment		(36	)		(362	)		(190	)		(362	)
Non-GAAP operating expenses	$	12,800		$	19,447		$	25,737		$	38,865

R&D operating expenses	$	5,850		$	11,978		$	11,738		$	20,350
Stock-based compensation expense		(479	)		(2,190	)		(881	)		(3,112	)
Depreciation and amortization		(392	)		(658	)		(843	)		(1,370	)
Loss on disposal of property and equipment		(26	)		—			(166	)		—
Non-GAAP R&D operating expenses	$	4,953		$	9,130		$	9,848		$	15,868

SG&A operating expenses	$	8,295		$	12,814		$	17,099		$	33,343
Stock-based compensation expense		(373	)		(1,057	)		(680	)		(8,101	)
Amortization of acquired intangible assets		(164	)		(238	)		(345	)		(311	)
Depreciation and amortization		99			(840	)		(161	)		(1,572	)
Loss on disposal of property and equipment		(10	)		(362	)		(24	)		(362	)
Non-GAAP SG&A operating expenses	$	7,847		$	10,317		$	15,889		$	22,997

STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Discontinued Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Net loss	$	(15,786	)	$	(20,274	)	$	(18,449	)	$	(36,027	)
Income tax (benefit) expense		(125	)		16			(157	)		31
Interest income		—			—			—			—
Interest expense		—			—			—			—
Amortization of acquired intangible assets		817			790			1,715			1,415
Depreciation and amortization		1,172			2,133			2,356			4,234
Bargain purchase gain		—			—			—			—
Restructuring and related charges		104			—			104			—
Transaction and integration expenses		10,507			—			10,507			—
Stock-based compensation expense		1,013			3,320			1,975			11,363
Cost of sales adjustment		—			—			—			(1,812	)
Loss on disposal of property and equipment		62			362			248			362
Other non-operating (income) expense		(196	)		—			(3,500	)		—
Adjusted EBITDA	$	(2,432	)	$	(13,653	)	$	(5,201	)	$	(20,434	)

STANDARD BIOTOOLS INC. Condensed Combined Results of Operations Continuing Operations and Discontinued Operations (In thousands) (Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Revenue	$	41,962		$	37,205		$	82,757		$	82,745
Cost of revenue		22,686			22,294			43,739			43,650
Selling, general and administrative expenses		36,321			37,709			75,028			84,652
Research and development		12,072			19,221			23,400			35,202
Transaction and integration expenses		10,778			2,782			11,981			19,945
Restructuring		1,727			5,749			3,279			10,033
Other (income) expense, net		(8,163	)		(4,832	)		(15,178	)		(32,862	)
Total expenses	$	75,421		$	82,923		$	142,249		$	160,620
Net loss	$	(33,459	)	$	(45,718	)	$	(59,492	)	$	(77,875	)

STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Continuing Operations and Discontinued Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Gross profit	$	19,277		$	14,908		$	39,019		$	39,096
Amortization of acquired intangible assets		653			555			1,370			2,511
Depreciation and amortization		1,433			967			2,169			1,991
Stock-based compensation expense		563			294			1,058			533
Loss on disposal of property and equipment		213			—			245			—
Cost of sales adjustment		—			—			—			(1,812	)
Non-GAAP gross profit	$	22,139		$	16,724		$	43,861		$	42,319

Gross margin percentage		45.9	%		40.1	%		47.1	%		47.2	%
Amortization of acquired intangible assets		1.6	%		1.5	%		1.7	%		3.0	%
Depreciation and amortization		3.5	%		2.6	%		2.6	%		2.4	%
Stock-based compensation expense		1.3	%		0.8	%		1.3	%		0.6	%
Loss on disposal of property and equipment		0.5	%		—			0.3	%		—
Cost of sales adjustment		—			—			—			(2.1	)%
Non-GAAP gross margin percentage		52.8	%		45.0	%		53.0	%		51.1	%

STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Continuing Operations and Discontinued Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Operating expenses	$	61,081		$	65,427		$	113,792		$	149,797
Restructuring and related charges		(1,831	)		(5,749	)		(3,383	)		(10,033	)
Transaction and integration expenses		(10,778	)		(2,782	)		(11,981	)		(19,945	)
Stock-based compensation expense		(5,822	)		(6,436	)		(14,338	)		(17,808	)
Amortization of acquired intangible assets		(164	)		(161	)		(345	)		(311	)
Depreciation and amortization		(1,744	)		(2,172	)		(4,281	)		(4,237	)
Loss on disposal of property and equipment		(36	)		(371	)		(190	)		(385	)
Non-GAAP operating expenses	$	40,706		$	47,756		$	79,274		$	97,078

R&D operating expenses	$	12,072		$	19,222		$	23,400		$	35,202
Stock-based compensation expense		(960	)		(2,428	)		(1,701	)		(3,756	)
Depreciation and amortization		(1,022	)		(788	)		(1,612	)		(1,659	)
Loss on disposal of property and equipment		30			—			(138	)		—
Non-GAAP R&D operating expenses	$	10,120		$	16,006		$	19,949		$	29,787

SG&A operating expenses	$	36,400		$	37,674		$	75,028		$	84,617
Stock-based compensation expense		(4,862	)		(4,008	)		(12,637	)		(14,052	)
Amortization of acquired intangible assets		(164	)		(161	)		(345	)		(311	)
Depreciation and amortization		(722	)		(1,384	)		(2,669	)		(2,578	)
Loss on disposal of property and equipment		(66	)		(371	)		(52	)		(385	)
Non-GAAP SG&A operating expenses	$	30,586		$	31,750		$	59,325		$	67,291

STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Continuing Operations and Discontinued Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Net loss	$	(33,459	)	$	(45,718	)	$	(59,492	)	$	(77,875	)
Income tax (benefit) expense		(734	)		55			(885	)		183
Interest income		(2,461	)		(5,302	)		(5,377	)		(11,509	)
Interest expense		9			858			11			1,891
Amortization of acquired intangible assets		817			716			1,715			2,822
Depreciation and amortization		3,177			3,139			6,450			6,228
Bargain purchase gain		—			—			—			(25,213	)
Restructuring and related charges		1,831			5,749			3,383			10,033
Transaction and integration expenses		10,778			2,782			11,981			19,945
Stock-based compensation expense		6,385			6,730			15,396			18,341
Cost of sales adjustment		—			—			—			(1,812	)
Loss on disposal of property and equipment		249			371			435			385
Other non-operating (income) expense		(5,159	)		(412	)		(9,030	)		1,822
Adjusted EBITDA	$	(18,567	)	$	(31,032	)	$	(35,413	)	$	(54,759	)